[HTML][HTML] Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial
S Ständer, P Kwon, J Hirman, AJ Perlman… - Journal of the American …, 2019 - Elsevier
Background Anecdotal evidence suggests that neurokinin 1 receptor antagonism reduces
pruritus intensity in chronic pruritic conditions such as prurigo nodularis (PN). Objective This
study assessed safety and efficacy of the neurokinin 1 receptor antagonist serlopitant for
treatment of pruritus in PN. Methods In this randomized, double-blind, placebo-controlled
study, 128 patients with chronic, treatment-refractory PN for more than 6 weeks received
serlopitant, 5 mg, or placebo orally once daily for 8 weeks. The primary end point was …
pruritus intensity in chronic pruritic conditions such as prurigo nodularis (PN). Objective This
study assessed safety and efficacy of the neurokinin 1 receptor antagonist serlopitant for
treatment of pruritus in PN. Methods In this randomized, double-blind, placebo-controlled
study, 128 patients with chronic, treatment-refractory PN for more than 6 weeks received
serlopitant, 5 mg, or placebo orally once daily for 8 weeks. The primary end point was …